Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 136.50 INR
Change Today +0.60 / 0.44%
Volume 16.6K
BLIS On Other Exchanges
Symbol
Exchange
BLIS is not on other exchanges.
As of 12:34 AM 04/22/15 All times are local (Market data is delayed by at least 15 minutes).

bliss gvs pharma ltd (BLIS) Snapshot

Open
135.90
Previous Close
135.90
Day High
137.00
Day Low
135.00
52 Week High
04/13/15 - 146.00
52 Week Low
05/28/14 - 38.95
Market Cap
14.1B
Average Volume 10 Days
681.2K
EPS TTM
3.97
Shares Outstanding
103.1M
EX-Date
02/24/15
P/E TM
34.4x
Dividend
0.70
Dividend Yield
0.51%
Current Stock Chart for BLISS GVS PHARMA LTD (BLIS)

Related News

No related news articles were found.

bliss gvs pharma ltd (BLIS) Related Businessweek News

No Related Businessweek News Found

bliss gvs pharma ltd (BLIS) Details

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers therapeutic products, such as anti-fungal, laxative, anti-haemorrhoidal, anti-spasmodic, anti-malarial, anti-biotic, anti-microbial, anthelmintic, anti-diarrhoeal, anti-inflammatory, anti-pyretic, analgesic, anti-diabetic, anti-hypertensive, anti-emetic, anti-depressant, erectile dysfunction, multivitamin, anti-allergic, and antacid. It also provides over-the counter products, including herbal lozenges, shampoos, medicated dusting powders, herbal roll on products, and medicated and moisturizing soaps. In addition, the company provides female contraceptive under the Today brand name; and contract manufacturing services, as well as trades in pharmaceuticals. The company offers its products in various dosage forms, such as suppositories; pessaries; tablets; capsules; suspensions; syrups; dry powder injectables; injectables in ampoules; eye/ear/nasal drops; soft gelatin capsules; creams, gels, and ointments; and transdermal patches. The company was incorporated in 1984 and is based in Mumbai, India.

Founded in 1984

bliss gvs pharma ltd (BLIS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bliss gvs pharma ltd (BLIS) Key Developments

Bliss GVS Pharma Limited Approves Interim Dividend

Bliss GVS Pharma Limited in its board meeting held on February 12, 2015, approved interim dividend of INR 0.20 per share of face value of INR 1 each. The dividend will be given to the share holders whose name will appear on the record date. Record date fix for payment of interim dividend is February 25, 2015.

Bliss GVS Pharma Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Bliss GVS Pharma Limited reported unaudited earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company's net sales were INR 841.300 million compared to INR 588.577 million last year. Profit from operations before other income and finance cost and exceptional items was INR 231.323 million compared to INR 180.682 million last year. Profit from ordinary activities before tax INR 276.188 million compared to INR 173.142 million last year. Net profit after tax INR 179.926 million compared to INR 106.284 million last year. Basic and diluted EPS (not annualized) was INR 1.74, compared to INR 1.03 for the last year. For the nine months, the company's net sales were INR 2,414.957 million compared to INR 2,297.612 million last year. Profit from operations before other income and finance cost and exceptional items was INR 712.107 million compared to INR 574.079 million last year. Profit from ordinary activities before tax INR 805.783 million compared to INR 780.640 million last year. Net profit after tax INR 535.544 million compared to INR 524.121 million last year. Basic and diluted EPS (not annualized) was INR 5.19, compared to INR 5.08 for the last year.

Bliss Gvs Pharma Limited to Report Q3, 2015 Results on Feb 12, 2015

Bliss Gvs Pharma Limited announced that they will report Q3, 2015 results on Feb 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLIS:IN 136.50 INR +0.60

BLIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLIS.
View Industry Companies
 

Industry Analysis

BLIS

Industry Average

Valuation BLIS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLISS GVS PHARMA LTD, please visit www.blissgvspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.